Special Opportunities Fund
Mark is a Portfolio Director working with companies in the HP Special Opportunities Fund. Mark is a Life Sciences and Healthcare expert with a background that spans research, finance and operations.
Prior to joining the team, Mark was COO of a portfolio company, BrYet Ltd, commercialising a novel cancer therapy. Before this, Mark was responsible for research and insight in the Life Sciences sector at Deloitte. He also held a number of research and policy roles at Imperial College, UCSF and University of Washington.
Mark holds a Bachelor of Science degree from the University of Washington and a PhD in Bioengineering from UCSF.